A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
AMG 224
Sponsor
Amgen